Interestingly, we detected five neuroblastomas with amplified MYCN in the early-MRCA class, and, remarkably, all of these patients survived until the end of the observation periods (1,447–4,177 days), in contrast to the poor survival of patients with MYCN-amplified tumors in the late-MRCA group. This evidence concerns the gene MYCN and neuroblastoma.